Eyelash extensions may cause ocular disorders

Article

Ocular disorders such as keratoconjunctivitis and allergic blepharitis can be caused by wearing eyelash extensions.

Ocular disorders such as keratoconjunctivitis and allergic blepharitis can be caused by wearing eyelash extensions, reports a new study in the journal Cornea.

The retrospective investigation, compiled by Dr Yuki Amano and his team, Department of Ophthalmology, University of Tokyo, Graduate School of Medicine, Japan, involved 107 female patients with ocular complaints caused by eyelash extensions. Each patient had visited ophthalmologic clinics between March 2007 and March 2010. None of the patients had a history of eye disease and were aged between 21 years and 60 years.

The findings revealed that ocular disorders keratoconjunctivitis caused by invasion of glue or removing agents occurred in 64 patients. A further 42 patients experienced allergic blepharitis caused by eyelash extension glues.

Three patients presented with conjunctival erosion due to eyelid-fixing tapes, 1 patient had allergic blepharitis due to eyelid-fixing tapes and 1 patient experienced subconjunctival haemorrhage due to compression during eyelash extension removal.

Eye drops and ointments were used to treat all patients and the eyelash extension glue ingredient that caused the most ocular damage was formaldehyde.

The study suggests that the ingredients of eyelash glue should be improved, along with the ophthalmologic knowledge of physicians.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.